LITS

#4418
Lite Strategy, Inc. - Common Stock
0.9 8 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.98
0.98
Jahresspanne
0.69
3.23
Tagesänderung
-2.00%
Monatliche Änderung
-1.01%
6 month change
-9.26%
Jahresänderung
-67.11%
Vorheriger Schlusskurs
1.0 0
Open
0.9 8
Tief
0.9 8
Hoch
0.9 8
Volumen
2
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Lite Strategy, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Lite Strategy, Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K

2025

Quarterly report, Q2 FY2025
Lite Strategy, Inc. quarterly report, Q2 FY2025
10-Q
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K

Lite Strategy, Inc. current report, 01 June 2023

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on June 1, 2023. The filing addresses Item 8.01 (Other Events) regarding the rejection of an unsolicited acquisition proposal and provides updates on a proposed merger with Infinity Pharmaceuticals, Inc.

Key Financial Metrics

This filing is a current report regarding corporate events and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. Specific financial data for the reporting period is not provided in this document.

Material Changes and Corporate Events

  • Rejection of Unsolicited Proposal: On June 1, 2023, the Board of Directors rejected a non-binding proposal received on May 23, 2023, from a group represented by Anson Advisors Inc. and Cable Car Capital LLC.
  • Proposal Terms Rejected: The rejected offer was for not less than $8.00 in cash per share, plus a contingent value right (CVR) entitling holders to 80% of net proceeds from any license or disposition of MEI's clinical assets.
  • Proposed Merger with Infinity: The filing references an ongoing proposed transaction between MEI Pharma and Infinity Pharmaceuticals, Inc., for which a joint proxy statement/prospectus is expected to be filed.

Outlook, Risks, and Management Commentary

Management directs investors to the upcoming Joint Proxy Statement/Prospectus for detailed information regarding the proposed merger with Infinity Pharmaceuticals. The filing includes extensive forward-looking statements and risk factors, including:

  • Risks that the proposed merger may not be completed in a timely manner or at all.
  • Uncertainties regarding stockholder and regulatory approvals.
  • Potential disruption to business operations, retention of key personnel, and management attention.
  • Risks related to the clinical development, regulatory approval, and commercialization of product candidates.
  • Exposure to economic factors, including inflation and market price fluctuations.

Investor Verification Checklist

  • Verify the status of the proposed merger with Infinity Pharmaceuticals, Inc. by reviewing the Joint Proxy Statement/Prospectus once filed.
  • Confirm the current cash runway and liquidity position of MEI Pharma in the most recent Form 10-Q or 10-K, as this 8-K does not provide financial figures.
  • Review the specific terms of the rejected $8.00 per share offer to understand the valuation context relative to current market prices.
  • Monitor regulatory filings for updates on the contingent value right (CVR) terms associated with the rejected proposal.
  • Check for any new unsolicited proposals or changes in the merger agreement with Infinity Pharmaceuticals.